What is Panacea Biotec's largest business segment?

Vaccines, with 3.10 billion INR or 55% of segment revenue in fiscal year 2025. Next: Formulations (45%).

Where does Panacea Biotec make most of its revenue?

Overseas: 72% of revenue by region in fiscal year 2025, followed by India (28%).

What companies are similar to Panacea Biotec?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Unichem Laboratories Limited (UNICHEMLAB.NS), Syncom Formulations (India) Limited (SYNCOMF.NS), Venus Remedies Limited (VENUSREM.NS), Indoco Remedies Limited (INDOCO.NS).

Panacea Biotec Limited (PANACEABIO.NS) Stock

About Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. The company operates through Vaccines and Pharmaceutical Formulations & Nutrition segments. Its product portfolio includes prescription products in various therapeuti...

At a glance

In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.65 billion INR, up 1.0% from a year before. Its largest business segment, Vaccines, brought in 55% of segment revenue in fiscal year 2025; Overseas was the largest region with 72%.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.